Why fund managers are watching Clarity Pharmaceuticals' Telix head-to-head trials
Clarity Pharmaceuticals' prostate cancer diagnostic has repeatedly outperformed Telix's in head-to-head trials, with fund managers estimating meaningful market share potential ahead of a 2028 launch.
30 Jun 2026 · 6 min read
In short
Clarity Pharmaceuticals' Co-PSMA trial detected prostate cancer lesions in 78% of patients versus 36% for the current gallium-68 standard of care.
The company raised $203 million in July 2025, bringing its pro forma cash balance to approximately $288 million to fund multiple Phase III trials.
Pengana Capital Group estimates the prostate cancer diagnostic market could reach US$3 billion by 2029, with Clarity able to reasonably capture 10-20% market share.
Radiopharmaceutical developer Clarity Pharmaceuticals has delivered a series of head-to-head trial results suggesting its prostate cancer diagnostic outperforms the current standard of care from Telix Pharmaceuticals. Perennial Partners' February 2026 Monthly Report detailed abstract data from the Co-PSMA study presented at the European Association of Urology conference, showing Clarity's 64Cu-SAR-bisPSMA detected lesions in 78% of patients compared with 36% using the gallium-68 tracer, with treatment plan changes resulting in 44% of cases.
A differentiated diagnostic with a well-funded pipeline
SG Hiscock & Company's July 2025 Monthly Report detailed the balance sheet position underpinning the story: a $203 million capital raise completed at a premium to the prior close, bringing the company's pro forma cash balance to approximately $288 million and fully funding multiple Phase III trials and commercial readiness activities. Blackwattle Investment Partners' October 2025 Monthly Report described the initial head-to-head trial result as a potential game changer for the industry, since Clarity's product found meaningfully more lesions per patient than the incumbent Telix diagnostic, given higher sensitivity and an ability to identify smaller tumours.
For a debt-free, growing gold producer with one of the sector's best management teams, we believe this represents a compelling risk-reward opportunity.
— Cerutty Macro Fund, Monthly Report, July 2025
Pengana Capital Group's February 2026 Monthly Report sized the commercial opportunity, estimating the prostate cancer diagnostic market could reach approximately US$3 billion by 2029, with Clarity able to reasonably capture 10-20% market share, a level that alone would support its then-market capitalisation of roughly A$1.3 billion, with additional upside from its separate prostate cancer therapeutic program. Ausbil Investment Management's September 2025 Quarterly Report drew a direct comparison to Telix's own product portfolio several years earlier, seeing similar characteristics in Clarity's differentiated pipeline heading into a large and growing radiopharmaceutical market.
What managers are watching next
The stock has proven highly volatile despite the string of positive trial results. Perennial Partners' successive 2026 monthly reports noted repeated share price declines on no identifiable company-specific news, attributing much of the movement to tax-loss selling and Australian Federal Budget capital gains tax changes rather than any change in the underlying trial trajectory. Pengana Capital Group's April 2026 report confirmed a manufacturing agreement with Nucleus RadioPharma to produce up to 600,000 doses annually of the Cu64 isotope, supplying all 50 US states and select European locations, with FDA approval expected around mid-2027 and commercial launch targeted for 2028.
Questions
How does Clarity Pharmaceuticals' diagnostic compare to Telix's?
In the Co-PSMA head-to-head trial, Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA diagnostic detected prostate cancer lesions in 78% of patients compared with 36% using the gallium-68 tracer similar to Telix's product, with the higher sensitivity resulting in treatment plan changes in 44% of cases.
How well funded is Clarity Pharmaceuticals?
Clarity Pharmaceuticals raised $203 million in July 2025, bringing its pro forma cash balance to approximately $288 million, fully funding multiple Phase III trials and commercial readiness activities across its radiopharmaceutical platform.
When could Clarity Pharmaceuticals launch its diagnostic commercially?
Pengana Capital Group expects Clarity Pharmaceuticals to receive FDA approval for its prostate cancer diagnostic around mid-2027, with a commercial launch targeted for 2028, supported by a manufacturing agreement with Nucleus RadioPharma.
7 managers, 34 comments, with each manager's latest recorded position.
See CU6